Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan

Sai-Cheong Lee*1,7, Shie-Shian Huang1,7, Chao-Wei Lee2, Chang-Phone Fung3,9, Ning Lee4, Wen-Bin Shieh5,8 and LK Siu6

Address: 1Division of Infectious Diseases, Chang Gung Memorial Hospital, Keelung, Taiwan, Republic of China, 2Department of Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan, Republic of China, 3Division of Infectious Diseases, Veterans General Hospital, Taipei, Taiwan, Republic of China, 4Department of Pathology, Chang Gung Memorial Hospital, Keelung, Taiwan, Republic of China, 5Department of Chest, Chang Gung Memorial Hospital, Keelung, Taiwan, Republic of China, 6Division of Clinical Research, National Health Research Institute, Miaoli County, Taiwan, Republic of China, 7Chang Gung Institute of Technology, Kwei-Shan Tao-Yuan., Taiwan, Republic of China, 8Chang Gung University, Kwei-Shan Tao-Yuan., Taiwan, Republic of China and 9National Yang-Ming University, Taipei, Taiwan, Republic of China

Email: Sai-Cheong Lee* - Lee.sch@msa.hinet.net; Shie-Shian Huang - super9281@yahoo.com.tw; Chao-Wei Lee - alanchaoweilee@hotmail.com; Chang-Phone Fung - IDS.ROC@msa.hinet.net; Ning Lee - Ruby800@cgmh.org.tw; Wen-Bin Shieh - madmasst@cgmh.org.tw; LK Siu - Leesc@url.com

* Corresponding author

Abstract

Background: Ertapenem is a once-a-day carbapenem and has excellent activity against many gram-positive and gram-negative aerobic, facultative, and anaerobic bacteria. The susceptibility of isolates of community-acquired bacteremia to ertapenem has not been reported yet. The present study assesses the in vitro activity of ertapenem against aerobic and facultative bacterial pathogens isolated from patients with community-acquired bacteremia by determining and comparing the MICs of cefepime, cefoxitin, ceftazidime, ceftriaxone, ertapenem, piperacillin, piperacillin-tazobactam, ciprofloxacin, amikacin and gentamicin. The prevalence of extended broad spectrum β-lactamases (ESBL) producing strains of community-acquired bacteremia and their susceptibility to these antibiotics are investigated.

Methods: Aerobic and facultative bacteria isolated from blood obtained from hospitalized patients with community-acquired bacteremia within 48 hours of admission between August 1, 2004 and September 30, 2004 in Chang Gung Memorial Hospital at Keelung, Taiwan, were identified using standard procedures. Antimicrobial susceptibility was evaluated by Etest according to the standard guidelines provided by the manufacturer and document M100-S16 Performance Standards of the Clinical Laboratory of Standard Institute. Antimicrobial agents including cefepime, cefoxitin, ceftazidime, ceftriaxone, ertapenem, piperacillin, piperacillin-tazobactam, ciprofloxacin, amikacin and gentamicin were used against the bacterial isolates to test their MICs as determined by Etest. For Staphylococcus aureus isolates, MICs of oxacillin were also tested by Etest to differentiate oxacillin-sensitive and oxacillin-resistant S. aureus.

Results: Ertapenem was highly active in vitro against many aerobic and facultative bacterial pathogens commonly recovered from patients with community-acquired bacteremia (128/159, 80.5 %). Ertapenem had more potent activity than ceftriaxone, piperacillin-tazobactam, or...
ciprofloxacin against oxacillin-susceptible *S. aureus* (17/17, 100%) and was more active than any of these agents against *enterobacteriaceae* (82/82, 100%).

**Conclusion:** Based on the microbiology pattern of community-acquired bacteremia, initial empiric treatment that requires coverage of a broad spectrum of both gram-negative and gram-positive aerobic bacteria, such as ertapenem, may be justified in moderately severe cases of community-acquired bacteremia in non-immunocompromised hosts.

---

**Background**

Ertapenem is a once-a-day parenteral β-lactam antimicrobial agent [1-6]. Preclinical in vitro studies have shown that this structurally unique carbapenem has excellent activity against many gram-positive and gram-negative aerobic, facultative, and anaerobic bacteria that, in general, are associated with community-acquired infections [1-6]. However, it has minimal activity against *Pseudomonas aeruginosa*, *Acinetobacter* species, and *enterococci* [1-6], and these pathogens usually are associated with nosocomial infections. Recent antimicrobial susceptibility surveillance data indicate that the organisms causing intra-abdominal, skin and soft tissue, and urinary tract infections and community-acquired pneumonia are highly susceptible to ertapenem in vitro [7-17]. However, the susceptibility of isolates of community-acquired bacteremia to ertapenem has not yet been reported. The objective of the present study is to assess the in vitro activity of ertapenem against aerobic and facultative bacterial pathogens isolated from patients with community-acquired bacteremia by determining and comparing the MICs of cefepime, cefoxitin, ceftazidime, ceftriaxone, ertapenem, piperacillin, piperacillin-tazobactam, ciprofloxacin, amikacin and gentamicin. In addition, the prevalence of ESBL producing strains of community-acquired bacteremia and their susceptibility to these antibiotics are investigated.

**Methods**

Chang Gung Memorial Hospital at Keelung is an 850-bed (including 55 ICU beds) teaching hospital offering a broad range of services in serving the healthcare needs of about 500,000 residents in northern Taiwan. It has approximately 21,000 admissions per year and mean duration of hospitalization of 8.2 days. Aerobic and facultative bacteria isolated from blood obtained from hospitalized patients with community-acquired bacteremia within 48 hours of admission between August 1, 2004 and September 30, 2004 in Chang Gung Memorial Hospital at Keelung were identified using standard procedures. Community-acquired bacteremia was diagnosed when clinically significant bacterial pathogens were isolated from the blood of hospitalized patients with fever of 38.0°C within 48 hours of admission and without admission in past two weeks. Cases with only one blood culture bottle positive for normal skin flora such as coag-

ulase-negative *staphylococci*, *Staphylococcus epidermidis*, *Staphylococcus saprophyticus* and *corynebacterium* spp. were excluded. All *bacillus*, *micrococcus* and *propionibacterium* isolates which were considered contaminants and anaerobic bacteria were excluded. Clinically significant aerobic bacterial isolates were collected and stored in tryptic soy broth and frozen at -70°C.

Antimicrobial susceptibility was evaluated by Etest according to the standard guidelines provided by the manufacturer and document M100-S16 Performance Standards of the Clinical Laboratory of Standard Institute (CLSI). Antimicrobial agents mentioned above were used against the bacterial isolates to test their MICs as determined by Etest (AB Biodisk, Solna, Sweden). The antimicrobial agents used for each bacteria strain vary from three to eleven (Table 1). For *S. aureus* isolates, MICs of oxacillin were also tested by Etest to differentiate oxacillin-sensitive and oxacillin-resistant *S. aureus*. Detection of meca gene using primers mecaA1 GTA GAA ATG ACT GAACGT CCG ATA A and mecaA2 CCA ATT CCA CAT TGT TTC GGT CTA A with polymerase chain reaction method and MICs of amoxicillin/clavulanic acid with Etest for ORSA isolates were also performed using standard procedure. E test was performed on Mueller-Hinton agar (*pneumococci* and *streptococci*: blood agar). The MICs were read at the point where the inhibition ellipse intersected the scale on the strip after incubation at 35°C for 24 hours. Macrocolonies within the ellipse were regarded as significant growth whereas microcolonies could be neglected.

For quality control, standard control strains were included with each test run. The following organisms with acceptable MICs (µg/ml) limits were included as control strains according to CLSI M7-A7 [18]: *S. aureus* ATCC 29213 (0.12–0.5 for ciprofloxacin, 4–16 for ceftazidime, 1–4 for cefepime, 0.25/4–2/4 for piperacillin/tazobactam), *E. coli* ATCC 25922 (0.004–0.016 for ciprofloxacin, 0.06–5 for ceftazidime, 0.016–0.12 for cefepime, 1/4–4/4 for piperacillin/tazobactam), *P. aeruginosa* ATCC 27853 (0.25–1 for ciprofloxacin, 1–4 for ceftazidime, 1–8 for cefepime, 1/4–8/4 for piperacillin/tazobactam), *Streptococcus pneumoniae* ATCC 49619 (0.06–0.25 for cefepime), *Enterococcus faecalis* ATCC 29212 (0.25–2 for ciprofloxacin, 1/4–4/4 for piperacillin/tazobactam).
According to CLSI M7-A7, MIC(µg/ml) breakpoints of susceptibility for each type of bacteria were listed in Table 1.

S. aureus isolates with oxacillin MIC of $\leq 2$ µg/ml were regarded as oxacillin-sensitive S. aureus (OSSA), whereas isolates with oxacillin MIC of $\geq 4$ µg/ml were regarded as oxacillin-resistant S. aureus (ORSA) according to criteria of S. aureus susceptibility to oxacillin in CLSI document. M7-A7 published in January 2006. Enterobacteriaceae isolates with ceftazidime MIC $\geq 2$ µg/ml but MIC diminished at least 3 fold after addition of clavulanic acid were regarded as ESBL strains.

**Results and discussion**

There were 70 male and 89 female. Ages ranged from 1 year to 95 years with mean 60.9 years. There were 147 adults (age $\geq 17$ years, range 22–95 years, mean 65.2 years) and 12 pediatric patients (age $\leq 16$ years, range 1–16 years, mean 3.2 years). Of the 159 cases of community-acquired bacteremia, the most likely primary foci of origin according to clinical manifestations are urinary tract infection 59, pneumonia 39, biliary tract infection 17, cellulitis 9, infective endocarditis 3, osteomyelitis 2, peritonitis 1, gastroenteritis 1, and esophagitis 1. The primary foci of origin of the remaining 27 cases of community-acquired bacteremia are unknown. A total of 159 aerobic bacterial pathogens from 159 patients enrolled at Chang Gung Memorial Hospital were collected. Most (95/159, 59.7%) of the isolates were facultative gram-negative bacilli. The most common organism found was E. coli, which accounted for 26.4% (42/159) of the total. There were only seven isolates (7/159, 4.4%) with ESBLs (E. coli – ESBL, 4; K. pneumoniae – ESBL, 3).

Figure 1 shows the distribution of ertapenem MIC values for all bacteria isolates tested. Among all the collected isolates, 128 out of 159 isolates (80.5%) were susceptible to ertapenem (MICs $\leq 2$ µg/ml) and 19.5 % was resistant (MICs $\geq 4$ µg/ml). 112 out of 159 isolates (70.4%) were susceptible to ceftazidime (MICs $\leq 8$ µg/ml). Among the 82 enterobacteriaceae isolates, including the ESBL strains, all (100%) were susceptible to ertapenem while 71 (86.6%) was susceptible to ceftazidime (Additional file 1). All seven ESBL strains including four E. coli -ESBL and three K. pneumoniae -ESBL isolates were susceptible to ertapenem, ceftazidime/clavulanic acid and ceftoxime-clavulanic acid (Additional file 1). Seven isolates of coagulase-negative staphylococci were repetitively isolated from seven patients and were thus regarded as significant isolates. Three of these seven isolates were susceptible to ertapenem (Additional file 1). Included in the ertapenem-resistant group were enterococci, oxacillin-resistant S. aureus, oxacillin-resistant coagulase-negative staphylococci, P. aeruginosa and other non-fermentative gram-negative bacilli (Table 1). Of the two ORSA isolates that were susceptible in vitro to amikacin, one was also susceptible to ciprofloxacin and gentamicin (Additional file 1). Antimicrobial activities of ertapenem and the comparator agents against all bacteria tested are summarized in Additional file 1. All MICs of control strains obtained with Etest were within the acceptable range listed by CLSI M7A7.

Although most OSSA were susceptible to the majority of agents tested, ertapenem had the most potent activity, based on values for inhibition of 50 % (MIC$_{50}$) and 90% (MIC$_{90}$) of the isolates. All isolates of OSSA were susceptible to ertapenem (17/17, 100 %). Ertapenem was the most active agent against enterobacteriaceae and demonstrated high potency based on MIC$_{50}$ and MIC$_{90}$ values. All isolates of enterobacteriaceae, including most ESBL strains, were susceptible to ertapenem (82/82, 100%) while not as susceptible to ceftazidime (86.6 %). Among these 159 isolates, there were 38 E. coli isolates of which 4 (10.5%) were ESBL strains, and 13 K. pneumoniae isolates, of which 3 (23%) were ESBL strains. The prevalence of enterobacteriaceae with ESBLs in community-acquired bacteremia was 7/159, 4.4% in this study. In our hospital, there were 877 significant isolates including fungus, aerobic and anaerobic bacteria causing nosocomial infections.

---

**Table 1: MIC(µg/ml) breakpoints of susceptibility for each type of bacteria**

| Type of bacteria /Antibiotic | FEP | FOX | CAZ | CRO | ERT | PIP | TAZO | CIP | AN | GM |
|-----------------------------|-----|-----|-----|-----|-----|-----|------|-----|-----|-----|
| Staphylococci               | ≤8  | ≤8  | ≤8  | ≤8  | ≤2  | ≤16 | ≤8/4 | ≤1  | ≤16 | ≤4  |
| Streptococci                | ≤1  | ≤1  | ≤8  | ≤8  | ≤1  | ≤8/4 | ≤1   | ≤1   | ≤16 | ≤4  |
| Enterococci                 | ≤8  | ≤8  | ≤8  | ≤8  | ≤16 | ≤8/4 | ≤1   | ≤1   | ≤16 | ≤4  |
| Enterobacteriaceae          | ≤8  | ≤8  | ≤8  | ≤8  | ≤2  | ≤16 | ≤16/4 | ≤1  | ≤16 | ≤4  |
| Non-fermenters              | ≤8  | ≤8  | ≤8  | ≤8  | ≤2  | ≤16 | ≤16/4 | ≤1  | ≤16 | ≤4  |

FEP = cefepime, FOX = cefoxitin, CAZ = ceftazidime, CRO = ceftaxoine, ERT = ertapenem, PIP = piperacillin, TAZO = piperacillin-tazobactam, CIP = ciprofloxacin, AN = amikacin GM = gentamicin, MIC = minimal inhibitory concentrations, $\leq$ indicates less than or equal to.

* For P. aeruginosa, MIC susceptibility breakpoint of piperacillin-tazobactam is $\leq 64/4 \mu$g/ml.

**Results and discussion**

There were 70 male and 89 female. Ages ranged from 1 year to 95 years with mean 60.9 years. There were 147 adults (age $\geq 17$ years, range 22–95 years, mean 65.2 years) and 12 pediatric patients (age $\leq 16$ years, range 1–16 years, mean 3.2 years). Of the 159 cases of community-acquired bacteremia, the most likely primary foci of origin according to clinical manifestations are urinary tract infection 59, pneumonia 39, biliary tract infection 17, cellulitis 9, infective endocarditis 3, osteomyelitis 2, peritonitis 1, gastroenteritis 1, and esophagitis 1. The primary foci of origin of the remaining 27 cases of community-acquired bacteremia are unknown. A total of 159 aerobic bacterial pathogens from 159 patients enrolled at Chang Gung Memorial Hospital were collected. Most (95/159, 59.7%) of the isolates were facultative gram-negative bacilli. The most common organism found was E. coli, which accounted for 26.4% (42/159) of the total. There were only seven isolates (7/159, 4.4%) with ESBLs (E. coli – ESBL, 4; K. pneumoniae – ESBL, 3).

Figure 1 shows the distribution of ertapenem MIC values for all bacteria isolates tested. Among all the collected isolates, 128 out of 159 isolates (80.5%) were susceptible to ertapenem (MICs $\leq 2$ µg/ml) and 19.5 % was resistant (MICs $\geq 4$ µg/ml). 112 out of 159 isolates (70.4%) were susceptible to ceftazidime (MICs $\leq 8$ µg/ml). Among the 82 enterobacteriaceae isolates, including the ESBL strains, all (100%) were susceptible to ertapenem while 71 (86.6%) was susceptible to ceftazidime (Additional file 1). All seven ESBL strains including four E. coli -ESBL and three K. pneumoniae-ESBL isolates were susceptible to ertapenem, ceftazidime/clavulanic acid and ceftoxime-clavulanic acid (Additional file 1). Seven isolates of coagulase-negative staphylococci were repetitively isolated from seven patients and were thus regarded as significant isolates. Three of these seven isolates were susceptible to ertapenem (Additional file 1). Included in the ertapenem-resistant group were enterococci, oxacillin-resistant S. aureus, oxacillin-resistant coagulase-negative staphylococci, P. aeruginosa and other non-fermentative gram-negative bacilli (Table 1). Of the two ORSA isolates that were susceptible in vitro to amikacin, one was also susceptible to ciprofloxacin and gentamicin (Additional file 1). Antimicrobial activities of ertapenem and the comparator agents against all bacteria tested are summarized in Additional file 1. All MICs of control strains obtained with Etest were within the acceptable range listed by CLSI M7A7.

Although most OSSA were susceptible to the majority of agents tested, ertapenem had the most potent activity, based on values for inhibition of 50 % (MIC$_{50}$) and 90% (MIC$_{90}$) of the isolates. All isolates of OSSA were susceptible to ertapenem (17/17, 100 %). Ertapenem was the most active agent against enterobacteriaceae and demonstrated high potency based on MIC$_{50}$ and MIC$_{90}$ values. All isolates of enterobacteriaceae, including most ESBL strains, were susceptible to ertapenem (82/82, 100%) while not as susceptible to ceftazidime (86.6 %). Among these 159 isolates, there were 38 E. coli isolates of which 4 (10.5%) were ESBL strains, and 13 K. pneumoniae isolates, of which 3 (23%) were ESBL strains. The prevalence of enterobacteriaceae with ESBLs in community-acquired bacteremia was 7/159, 4.4% in this study. In our hospital, there were 877 significant isolates including fungus, aerobic and anaerobic bacteria causing nosocomial infections.
in 2006. Among these 877 nosocomial isolates in our hospital in 2006, there were 151 E. coli isolates, of which 21 (14%) were ESBL strains, and 69 K. pneumoniae isolates, of which 22 (31.8%) were ESBL strains. The overall rate of ESBL strain among nosocomial isolates were 43/877 (4.9%). Although the overall rate of ESBL isolates among community-acquired bacteremia (4.4%) was close to that among nosocomial infections (4.9%), the rate of ESBL isolates among E. coli and K. pneumoniae were still higher in nosocomial infections. As expected, ertapenem and ceftriaxone had minimal activity against P. aeruginosa and enterococci. Among the nine ORSA isolates with oxacillin MICs ≥4 µg/ml, two ORSA isolates were mecA gene positive with amoxicillin/clavulanic acid MICs 32 µg/ml. The other seven ORSA isolates were mecA gene negative with amoxicillin/clavulanic acid MICs range 8–12 µg/ml, mean 11.4 µg/ml, indicating that mechanism of oxacillin resistance in these seven ORSA isolates was not due to mecA gene and was most likely due to hyperproduction of β-lactamases [19-22]. Two of the nine ORSA isolates were susceptible to amikacin, including one isolate that was also susceptible in vitro to ciprofloxacin and gentamicin; these two isolates resistant to all β-lactam antibiotics might lack resistance gene to other classes of antibiotics [19-22]. Based on the microbiology of community-acquired bacteremia, empiric treatment requires coverage of a broad spectrum of both gram-negative and gram-positive aerobic bacteria. In this in vitro study, ertapenem was the most active of the agents evaluated against the predominant pathogens – enterobacteriaceae and S. aureus. As anticipated, ertapenem had minimal activity against P. aeruginosa and enterococci, which was recovered relatively infrequently from community-acquired bacteremic infections. Because of the low frequency of isolation of P. aeruginosa and doubtful pathogenicity of enterococci in immune competent hosts, initial empiric antimicrobial regimens for bacteremic infections need not include agents specifically directed against these organisms. However, if P. aeruginosa is clearly identified as a pathogen in these patients, specific antipseudomonal coverage would be indicated.

**Conclusion**

In summary, ertapenem was highly active in vitro against many aerobic and facultative bacterial pathogens commonly recovered from patients with community-acquired bacteremia. Ertapenem had more potent activity than cefepime, cefoxitin, ceftriaxone and piperacillin-tazobactam against methicillin-susceptible S. aureus and was more active than any of these agents against enterobacteriaceae including strains with ESBL.

Community-acquired bacterial blood stream infections are common in clinical practice. Septicemia secondary to other foci of infections are caused by gram-negative and gram-positive aerobic and facultative bacteria, although E. coli and S. aureus remain the predominant pathogens. Non-fermentative gram-negative bacteria, which tend to be associated with nosocomial infections, are infrequently involved in community-acquired infections. Based on the microbiology pattern of community-acquired bacteremia, initial empiric treatment that requires coverage of a broad spectrum of both gram-negative and gram-positive aerobic bacteria, such as ertapenem, may be justified in moderately severe cases of community-acquired bacteremia in non-immunocompromised hosts. However, effect of ertapenem on the gut flora is still a concern.

**Authors’ contributions**

SCL designed the study, carried out the antimicrobial susceptibility studies with Etest and drafted the manuscript. SSH1 and CWL participated in the antimicrobial susceptibility studies. CPF participated in the design of the study. WBS participated in the statistical analysis. LKS assisted in the detection of mecA gene of oxacillin-resistant S. aureus with PCR. All authors read and approved the final manuscript.

**Additional material**

Additional file 1

*Comparative in vitro activity of ertapenem and comparator agents against aerobic and facultative bacteria isolated from patients with community-acquired bacteremia.*

Click here for file [http://www.biomedcentral.com/content.supplementary/1471-2334-7-79-S1.doc](http://www.biomedcentral.com/content.supplementary/1471-2334-7-79-S1.doc)
Acknowledgements
This study is financially supported by Chang Gung Memorial Hospital. We wish to thank Ms. Yi Mui Chan and Ms Hsiang Ju Shih for laboratory assistance and Ms. Chung Wei Lue for reviewing the English grammar of the manuscript.

References
1. Fuchs PC, Barry AL, Brown SD: In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001, 45:1915-1918.
2. Livermore DM, Carter MW, Bagel S, Wiedemann B, Saquero F, Loza E, Endtz HP, Nguyen J, Nord CE, Struelens MJ, Nonhoff C, Turnidge J, Bell J, Zbinden R, Pfister S, Mixson L, Shungu DL: In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001, 45:1860-1867.
3. Proust JR, Fairley L, Fleischer J: Ertapenem: the first group 1 carbapenem. Drugs Today 2005, 41:1-16.
4. PM, Isaac-O: Ertapenem: the first of a new group of carbapenems. J Antimicrob Chemother 2003, 52:538-542.
5. Livermore DM, Sefton AM, Scott GM: Properties and potential of ertapenem. J Antimicrob Chemother 2003, 52:331-344.
6. Weaker HH: In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 2004, 53(Suppl S2):ii32-i28.
7. Hilliard NJ, Johnson CN, Armstrong SH, Quarles S, Waite KB: In vitro activity of ertapenem(MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials. Int J Antimicrob Agents 2002, 20:136-140.
8. Livermore DM, Oakton KJ, Carter MW, Warner M: Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent-lactamases. Antimicrob Agents Chemother 2001, 45:2831-2837.
9. Guillermo OR, Caballero-Lopez J, Friedland IR, Gail LW, Carides A: Study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002, 34:1076-1083.
10. Goldstein EC, Citron DM, Merrian CV, Warren Y, Tyrrell KL, Gesser RM: General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. Activity of ertapenem in skin infections. Clin Infect Dis 2002, 35(Suppl 1):S119-S125.
11. Mandell LA, Bartlett, JD, Dowell SF, File TM, Musher DM, Whiteway C: Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Guidelines for CAP in adults. Clin Infect Dis 2003, 1:1405-1433.
12. Lipsky BA, Berendt AR, Deery HG, Embil JM, Warren SJ, Karchmer AW, LeFrock JL, Lewis DP, Mader JT, Norden C, Tan JS: Diagnosis and Treatment of Diabetic Foot Infections. Guidelines for diabetic foot infections. Clin Infect Dis 2004, 9:885-910.
13. Tellado J, Woods GL, Gesser R, McCarroll K, Teppler H: Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections. Surg Infect 2002, 3:303-314.
14. Alihamra1 A, Cuadros JA, Cacho J, Gómez-Garcés JL, Alów J: In vitro susceptibility of recent, antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother 2004, 53:1090-1094.
15. Mazuki JE, Sawyer RG, Nathens AB, Dipiro JT, Schein M, Kudsk KA, Yowler C: The surgical infection society guidelines on antimicrobial therapy for intra-abdominal infections. Surg Infect 2002, 3:161-173.
16. Solomon JS, Mazuki JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, Buchman T, Dellingler EP, Jernigan J, Gorbach S, Chow AW, Bartlett J: Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Treatment guidelines for intra-abdominal infections. Clin Infect Dis 2003, 37:997-1005.
17. Tomera KM, Burdmann EA, Reyna OGP, Jiang Q, Wimmer WM, Woods GL, Richard M: Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults. Antimicrob Agents Chemother 2002, 46:2895-2900.
18. Wiler MA, Low DE, Cockerill FR, Sheetan DJ, Craig WA, Tenover FC, Dudley MN: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically:approved standard-seventh edition. CLSI (formerly NCCLS) 2006:M7-A7.
19. Huang MB, Gay TE, Baker CN, Bannereje SN, Tenover FC. Two percent sodium chloride is required for susceptibility testing of staphylococci with oxacillin when using agar-based dilution methods. J Clin Microbiol 1993, 31:2683-2688.
20. Tomasz A, Drugeon HB, de Lacocetre HM, Jabs D, McDougal L, Bille J: New mechanism for methicillin resistance in Staphylococcus aureus:clinical isolates that lack the PBP 2a gene and contain normal penicillin-binding capacity. Antimicrob Agents Chemother 1989, 33:1869-1874.
21. Ubukata K, Nakagami S, Nitta A, Yamane A, Kawakami S, Sugiura M, Konno A: Rapid detection of the mecA gene in methicillin-resistant staphylococci by enzymatic detection of polymerase chain reaction products. Clin Microbiol 1992, 30(7):1728-1733.
22. Rybak MJ, LaPente KL: Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacother 2005, 25:74-85.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/7/79/prepub

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
• available free of charge to the entire biomedical community
• peer reviewed and published immediately upon acceptance
• cited in PubMed and archived on PubMed Central
• yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp